Editorial: Hallucinogens and Entactogens: Establishing a New Class of Psychotherapeutic Drugs?
Year: 2020
Type: editorial
Abstract: LSD. Furthermore, related substances like ibogaine and ayahuasca are investigated systematically for the first time and this is also true for the therapeutic use of MDMA.Previous findings suggest that a few administrations of these substances might improve symptoms of these disorders in an enduring way, outlasting the acute pharmacological effects by far. It is often assumed, that the underlying mechanisms are similar to those which are effective in psychotherapy. This mechanism of action would be unique in psychopharmacology, constituting a new class of psychotherapeutic drugs.Especially the potential therapeutic applications have become the focus of attention in the public and the scientific community. Although psychiatry has progressed greatly during the twentieth century, there are still patients who do not respond well to established interventions and are therefore considered treatment-resistant. Moreover, psychopharmacological treatments are often accompanied by side effects, posing a challenge for compliance. Overall, this issue covers a broad spectrum of questions relevant for clinical research and application of hallucinogens and entactogens. We hope, that this collection contributes to the great progress this field has seen in recent years.
Source: Frontiers in Psychiatry
Language: English
Subfield: Clinical Psychology
Field: Psychology
Domain: Social Sciences
Open Access status: gold
Estimated APC paid: $2,950
OpenAlex ID: W3029354975